Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Biogen › FMR LLC now owns 6.4% of BIIB as a passive investor Fund moves
Why it stands out A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Dec 31, 2025
Reporting period Not applicable
Filed with the SEC Feb 5, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000315066-26-000383
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Nov 10, 2025 5% stake STATE STREET CORPORATION reported a passive stake (13G) of 5.0% What came next Jan 13, 2026 Company filing · Form 8-K · Results Reported its results Jan 30, 2026 Congress Disclosed purchase of BIIB — reported range $1,001 - $15,000 Feb 2, 2026 Insider Officer sold ~$134K of BIIB shares in the open market Feb 5, 2026 5% stake FMR LLC reported a passive stake (13G) of 6.4% Feb 6, 2026 Company filing · Form 8-K · Results Reported its results Feb 9, 2026 Insider Officer sold ~$532K of BIIB shares in the open market Feb 11, 2026 Company filing · Form 8-K · Executive change, Other news Changed a top executive or board member, and reported other company news “On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”).” Feb 12, 2026 Insider · Their first buy on record Officer purchased ~$585 of BIIB shares in the open market Mar 11, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.” Mar 26, 2026 5% stake The Vanguard Group reported a passive stake (13G) Mar 27, 2026 FDA FDA drug approval: Spinraza Mar 31, 2026 Company filing · Form 8-K · Material agreement, Other news Signed an important agreement, and reported other company news Apr 6, 2026 Company filing · Form 8-K · Results Reported its results Apr 29, 2026 Company filing · Form 8-K · Results Reported its results Apr 29, 2026 5% stake Vanguard Capital Management reported a passive stake (13G) of 7.5%